ID   TET5A_HUMAN             Reviewed;         442 AA.
AC   Q96IP4; A8K7U4; Q5TF86; Q8NFZ9; Q9BW32; Q9NXV5;
DT   28-NOV-2006, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2008, sequence version 2.
DT   28-JUN-2023, entry version 135.
DE   RecName: Full=Terminal nucleotidyltransferase 5A {ECO:0000305};
DE            EC=2.7.7.19 {ECO:0000269|PubMed:33882302};
DE   AltName: Full=HBV X-transactivated gene 11 protein {ECO:0000303|Ref.2};
DE   AltName: Full=HBV XAg-transactivated protein 11 {ECO:0000303|Ref.2};
GN   Name=TENT5A {ECO:0000312|HGNC:HGNC:18345};
GN   Synonyms=C6orf37 {ECO:0000312|HGNC:HGNC:18345}, FAM46A
GN   {ECO:0000312|HGNC:HGNC:18345}, XTP11 {ECO:0000303|Ref.2};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT 39-GLY--GLY-43 DEL, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=12054608; DOI=10.1016/s0006-291x(02)00228-0;
RA   Lagali P.S., Kakuk L.E., Griesinger I.B., Wong P.W., Ayyagari R.;
RT   "Identification and characterization of C6orf37, a novel candidate human
RT   retinal disease gene on chromosome 6q14.";
RL   Biochem. Biophys. Res. Commun. 293:356-365(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS GLY-ASP-PHE-GLY-GLY-24
RP   INS AND ALA-313.
RC   TISSUE=Synovium;
RA   Liu Y., Li J., Cheng J., Ji D., Gong M., Zhang L., Chen J.;
RT   "Homo sapiens HBV XAg-transactivated protein 11 (XTP11) mRNA.";
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANTS
RP   GLY-ASP-PHE-GLY-GLY-24 INS AND ALA-313.
RC   TISSUE=Colon, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   GLY-ASP-PHE-GLY-GLY-24 INS.
RC   TISSUE=Eye, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CATALYTIC ACTIVITY, FUNCTION, AND MUTAGENESIS OF ASP-139 AND ASP-141.
RX   PubMed=33882302; DOI=10.1016/j.celrep.2021.109015;
RA   Gewartowska O., Aranaz-Novaliches G., Krawczyk P.S., Mroczek S.,
RA   Kusio-Kobialka M., Tarkowski B., Spoutil F., Benada O., Kofronova O.,
RA   Szwedziak P., Cysewski D., Gruchota J., Szpila M., Chlebowski A.,
RA   Sedlacek R., Prochazka J., Dziembowski A.;
RT   "Cytoplasmic polyadenylation by TENT5A is required for proper bone
RT   formation.";
RL   Cell Rep. 35:109015-109015(2021).
RN   [8]
RP   INVOLVEMENT IN OI18, VARIANTS OI18 ARG-127 AND GLY-231, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=29358272; DOI=10.1136/jmedgenet-2017-104999;
RA   Doyard M., Bacrot S., Huber C., Di Rocco M., Goldenberg A., Aglan M.S.,
RA   Brunelle P., Temtamy S., Michot C., Otaify G.A., Haudry C., Castanet M.,
RA   Leroux J., Bonnefont J.P., Munnich A., Baujat G., Lapunzina P., Monnot S.,
RA   Ruiz-Perez V.L., Cormier-Daire V.;
RT   "FAM46A mutations are responsible for autosomal recessive osteogenesis
RT   imperfecta.";
RL   J. Med. Genet. 55:278-284(2018).
RN   [9]
RP   VARIANTS GLY-ASP-PHE-GLY-GLY-24 INS AND 39-GLY--GLY-43 DEL.
RX   PubMed=16545789; DOI=10.1016/j.cca.2005.12.043;
RA   Cui J., Wang W., Lai M.D., Xu E.P., Lv B.J., Lin J., Ruan W.J., Ma Y.,
RA   Yao C.;
RT   "Identification of a novel VNTR polymorphism in C6orf37 and its association
RT   with colorectal cancer risk in Chinese population.";
RL   Clin. Chim. Acta 368:155-159(2006).
CC   -!- FUNCTION: Cytoplasmic non-canonical poly(A) RNA polymerase that
CC       catalyzes the transfer of one adenosine molecule from an ATP to an mRNA
CC       poly(A) tail bearing a 3'-OH terminal group and participates in the
CC       cytoplasmic polyadenylation (PubMed:33882302). Polyadenylates mRNA
CC       encoding extracellular matrix constituents and other genes crucial for
CC       bone mineralization and during osteoblast mineralization, mainly
CC       focuses on ER-targeted mRNAs (By similarity).
CC       {ECO:0000250|UniProtKB:D3Z5S8, ECO:0000269|PubMed:33882302}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + RNA(n) = diphosphate + RNA(n)-3'-adenine ribonucleotide;
CC         Xref=Rhea:RHEA:11332, Rhea:RHEA-COMP:14527, Rhea:RHEA-COMP:17347,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:33019, ChEBI:CHEBI:140395,
CC         ChEBI:CHEBI:173115; EC=2.7.7.19;
CC         Evidence={ECO:0000269|PubMed:33882302};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:11333;
CC         Evidence={ECO:0000269|PubMed:33882302};
CC   -!- INTERACTION:
CC       Q96IP4; P54253: ATXN1; NbExp=5; IntAct=EBI-954084, EBI-930964;
CC       Q96IP4; Q9NP31: SH2D2A; NbExp=3; IntAct=EBI-954084, EBI-490630;
CC       Q96IP4; P43405: SYK; NbExp=3; IntAct=EBI-954084, EBI-78302;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:D3Z5S8}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q96IP4-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96IP4-2; Sequence=VSP_035502;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with preferential expression
CC       observed in the retina compared to other ocular tissues
CC       (PubMed:12054608). Also expressed in osteoblasts (PubMed:29358272).
CC       {ECO:0000269|PubMed:12054608, ECO:0000269|PubMed:29358272}.
CC   -!- DISEASE: Osteogenesis imperfecta 18 (OI18) [MIM:617952]: An autosomal
CC       recessive form of osteogenesis imperfecta, a connective tissue disorder
CC       characterized by low bone mass, bone fragility and susceptibility to
CC       fractures after minimal trauma. Disease severity ranges from very mild
CC       forms without fractures to intrauterine fractures and perinatal
CC       lethality. Extraskeletal manifestations, which affect a variable number
CC       of patients, are dentinogenesis imperfecta, hearing loss, and blue
CC       sclerae. OI18 is a severe form characterized by congenital bowing of
CC       the lower limb, wormian bones, blue sclerae, vertebral collapses and
CC       multiple fractures in the first years of life.
CC       {ECO:0000269|PubMed:29358272}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the TENT family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH00683.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF350451; AAM53071.1; -; mRNA.
DR   EMBL; AY740520; AAW66943.1; -; mRNA.
DR   EMBL; AK000044; BAA90903.1; -; mRNA.
DR   EMBL; AK056057; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK292109; BAF84798.1; -; mRNA.
DR   EMBL; AL078599; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW48692.1; -; Genomic_DNA.
DR   EMBL; BC000683; AAH00683.1; ALT_INIT; mRNA.
DR   EMBL; BC007351; AAH07351.1; -; mRNA.
DR   CCDS; CCDS34489.1; -. [Q96IP4-1]
DR   PIR; JC7837; JC7837.
DR   RefSeq; NP_060103.2; NM_017633.2. [Q96IP4-1]
DR   PDB; 8EXE; X-ray; 3.50 A; A=64-394.
DR   PDB; 8EXF; X-ray; 3.22 A; A=64-394.
DR   PDBsum; 8EXE; -.
DR   PDBsum; 8EXF; -.
DR   AlphaFoldDB; Q96IP4; -.
DR   SMR; Q96IP4; -.
DR   BioGRID; 120744; 82.
DR   IntAct; Q96IP4; 48.
DR   STRING; 9606.ENSP00000318298; -.
DR   iPTMnet; Q96IP4; -.
DR   PhosphoSitePlus; Q96IP4; -.
DR   BioMuta; FAM46A; -.
DR   DMDM; 209572613; -.
DR   EPD; Q96IP4; -.
DR   jPOST; Q96IP4; -.
DR   MassIVE; Q96IP4; -.
DR   MaxQB; Q96IP4; -.
DR   PaxDb; Q96IP4; -.
DR   PeptideAtlas; Q96IP4; -.
DR   ProteomicsDB; 76841; -. [Q96IP4-1]
DR   ProteomicsDB; 76842; -. [Q96IP4-2]
DR   Antibodypedia; 46387; 123 antibodies from 20 providers.
DR   DNASU; 55603; -.
DR   Ensembl; ENST00000320172.11; ENSP00000318298.6; ENSG00000112773.16. [Q96IP4-1]
DR   Ensembl; ENST00000369754.7; ENSP00000358769.3; ENSG00000112773.16. [Q96IP4-2]
DR   GeneID; 55603; -.
DR   KEGG; hsa:55603; -.
DR   MANE-Select; ENST00000320172.11; ENSP00000318298.6; NM_017633.3; NP_060103.2.
DR   UCSC; uc003pjf.3; human. [Q96IP4-1]
DR   AGR; HGNC:18345; -.
DR   CTD; 55603; -.
DR   DisGeNET; 55603; -.
DR   GeneCards; TENT5A; -.
DR   HGNC; HGNC:18345; TENT5A.
DR   HPA; ENSG00000112773; Group enriched (bone marrow, salivary gland).
DR   MalaCards; TENT5A; -.
DR   MIM; 611357; gene.
DR   MIM; 617952; phenotype.
DR   neXtProt; NX_Q96IP4; -.
DR   OpenTargets; ENSG00000112773; -.
DR   Orphanet; 216812; Osteogenesis imperfecta type 3.
DR   PharmGKB; PA38531; -.
DR   VEuPathDB; HostDB:ENSG00000112773; -.
DR   eggNOG; KOG3852; Eukaryota.
DR   GeneTree; ENSGT00940000157191; -.
DR   HOGENOM; CLU_008115_2_1_1; -.
DR   InParanoid; Q96IP4; -.
DR   OrthoDB; 2946602at2759; -.
DR   PhylomeDB; Q96IP4; -.
DR   TreeFam; TF315239; -.
DR   BRENDA; 2.7.7.19; 2681.
DR   PathwayCommons; Q96IP4; -.
DR   SignaLink; Q96IP4; -.
DR   BioGRID-ORCS; 55603; 8 hits in 1149 CRISPR screens.
DR   ChiTaRS; FAM46A; human.
DR   GeneWiki; FAM46A; -.
DR   GenomeRNAi; 55603; -.
DR   Pharos; Q96IP4; Tbio.
DR   PRO; PR:Q96IP4; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q96IP4; protein.
DR   Bgee; ENSG00000112773; Expressed in parotid gland and 192 other tissues.
DR   ExpressionAtlas; Q96IP4; baseline and differential.
DR   Genevisible; Q96IP4; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:1990817; F:poly(A) RNA polymerase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0048255; P:mRNA stabilization; IBA:GO_Central.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; ISS:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0030278; P:regulation of ossification; ISS:UniProtKB.
DR   GO; GO:0009617; P:response to bacterium; IEA:Ensembl.
DR   InterPro; IPR012937; TET5.
DR   PANTHER; PTHR12974; PRION-LIKE- Q/N-RICH -DOMAIN-BEARING PROTEIN PROTEIN 44; 1.
DR   PANTHER; PTHR12974:SF25; TERMINAL NUCLEOTIDYLTRANSFERASE 5A; 1.
DR   Pfam; PF07984; NTP_transf_7; 1.
DR   SMART; SM01153; DUF1693; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Disease variant;
KW   Nucleotidyltransferase; Osteogenesis imperfecta; Reference proteome;
KW   Repeat; Transferase.
FT   CHAIN           1..442
FT                   /note="Terminal nucleotidyltransferase 5A"
FT                   /id="PRO_0000259929"
FT   REPEAT          24..28
FT                   /note="1"
FT   REPEAT          29..33
FT                   /note="2"
FT   REPEAT          34..38
FT                   /note="3"
FT   REPEAT          39..43
FT                   /note="4"
FT   VAR_SEQ         1
FT                   /note="M -> MHQRYFWTDQGQVALGGHYM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_035502"
FT   VARIANT         24
FT                   /note="G -> GGDFGG"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_046649"
FT   VARIANT         39..43
FT                   /note="Missing"
FT                   /evidence="ECO:0000269|PubMed:12054608,
FT                   ECO:0000269|PubMed:16545789"
FT                   /id="VAR_028978"
FT   VARIANT         127
FT                   /note="H -> R (in OI18; unknown pathological significance;
FT                   dbSNP:rs1187611948)"
FT                   /evidence="ECO:0000269|PubMed:29358272"
FT                   /id="VAR_080798"
FT   VARIANT         231
FT                   /note="D -> G (in OI18; unknown pathological significance;
FT                   dbSNP:rs1554200371)"
FT                   /evidence="ECO:0000269|PubMed:29358272"
FT                   /id="VAR_080799"
FT   VARIANT         313
FT                   /note="T -> A"
FT                   /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.2"
FT                   /id="VAR_028979"
FT   MUTAGEN         139
FT                   /note="D->N: Does not elongate poly(A) tail; when
FT                   associated with N-141."
FT                   /evidence="ECO:0000269|PubMed:33882302"
FT   MUTAGEN         141
FT                   /note="D->N: Does not elongate poly(A) tail; when
FT                   associated with N-139."
FT                   /evidence="ECO:0000269|PubMed:33882302"
FT   CONFLICT        47
FT                   /note="S -> T (in Ref. 1; AAM53071)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        145
FT                   /note="C -> S (in Ref. 1; AAM53071)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   442 AA;  49666 MW;  C72092C590C1E369 CRC64;
     MAEGEGYFAM SEDELACSPY IPLGGDFGGG DFGGGDFGGG DFGGGGSFGG HCLDYCESPT
     AHCNVLNWEQ VQRLDGILSE TIPIHGRGNF PTLELQPSLI VKVVRRRLAE KRIGVRDVRL
     NGSAASHVLH QDSGLGYKDL DLIFCADLRG EGEFQTVKDV VLDCLLDFLP EGVNKEKITP
     LTLKEAYVQK MVKVCNDSDR WSLISLSNNS GKNVELKFVD SLRRQFEFSV DSFQIKLDSL
     LLFYECSENP MTETFHPTII GESVYGDFQE AFDHLCNKII ATRNPEEIRG GGLLKYCNLL
     VRGFRPASDE IKTLQRYMCS RFFIDFSDIG EQQRKLESYL QNHFVGLEDR KYEYLMTLHG
     VVNESTVCLM GHERRQTLNL ITMLAIRVLA DQNVIPNVAN VTCYYQPAPY VADANFSNYY
     IAQVQPVFTC QQQTYSTWLP CN
//
